**Strong Sales Growth**: AbbVie's diverse portfolio achieved total net revenues of nearly $14.5 billion, reflecting a robust operational growth rate of 4.9%. Notably, the ex-Humira platform demonstrated an impressive growth of nearly 18%. Skyrizi and Rinvoq, key products in the immunology sector, saw combined sales projected to exceed $17 billion this year, surpassing initial expectations by $1.3 billion.
**Raised Revenue and EPS Guidance**: AbbVie raised its full-year revenue guidance by $500 million and adjusted earnings per share (EPS) guidance by $0.15, now expecting adjusted EPS between $10.90 and $10.94. This marks a total revenue increase of $1.8 billion since the initial guidance provided in February.
**Challenges with Humira**: Humira's global sales declined significantly, down 36.5% on an operational basis to $2.2 billion due to increasing biosimilar competition. While the erosion is in line with expectations, more Humira molecule volume is shifting to newer treatments than previously anticipated, contributing negatively to overall sales.